Sangamo Therapeutics filed for Chapter 11 bankruptcy and agreed to asset sale terms with Eli Lilly and Astellas as “stalking horse” bidders, seeking to monetize major parts of its platform. The agreements include Lilly’s acquisition of Sangamo’s capsid delivery platform, zinc-finger nuclease (ZFN) platform, modular integrase (MINT) platform, and the prion disease program ST-506, while Astellas will take Sangamo’s Fabry disease program isaralgagene civaparvovec (ST-920). Sangamo said other assets, including its clinical-stage ST-503 chronic neuropathic pain program and several cell and Treg assets, are expected to remain available for potential bidders at a future auction. The move highlights the financial fragility that can emerge in gene-editing platforms when clinical and partner timelines slip, and it signals a strategic consolidation opportunity for larger companies with execution and manufacturing scale.